Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia.

Lanthanum carbonate (LC), a newly developed non-calcium-containing phosphate binder, has been shown to possess high phosphate-binding capacity and safety when used for hyperphosphatemia in patients with chronic kidney disease undergoing dialysis. The effects of LC on bone metabolism in Japanese dialysis patients have not been investigated; therefore, we performed histomorphometric analysis on bone from dialysis patients with hyperphosphatemia. This was a prospective, open-label study in Japanese chronic kidney disease patients on dialysis, with a flexible daily dosage of 750-4500 mg to achieve target phosphorus levels of 3.